
Supply Chain Traceability of Medicinal Products
As per EUGMP requirements, EudraLex, Annex 16: Certification by a Qualified Person and Batch Release, the complete manufacturing and distribution
Warning letters, 483s, Recalls, Import Alerts, Audit observations
Please subscribe for latest posts and news with your email address.
Popular: Warning Letters, Recalls
The U.S. Food and Drug Administration (FDA) has issued a Warning Letter in June 2025 to Chinese drug manufacturer Yiling Pharmaceutical Ltd., (FEI 3011640199) citing serious deficiencies in equipment cleaning and inadequate cross-contamination prevention measures. The facility underwent inspection in...
The USFDA issued a notification on 22 May, 2025 on Data Integrity concerns on reliability and validity of biocompatibility testing and animal safety and performance testing studies conducted for Medical devices by third Party testing facilities. As per the notification...
Indian regulatory agency, CDSCO has updated the requirements for application and issuance of Export NOC for Unapproved Drugs / Unapproved New Drugs. As per the new procedure published by CDSCO on 7 May 2025, if the drug is approved by...
As per EUGMP requirements, EudraLex, Annex 16: Certification by a Qualified Person and Batch Release, the complete manufacturing and distribution
Author: Venkiteswaran.T.K The USFDA’s 2011 guidance on process validation advocates a life cycle approach and defines process validation activities in
In March 2025, Glenmark initiated recall of 23 products (148 lots) in US for cGMP deviations. The recall cover a
According to the EU GMP guidance—“Guidance for Risk Assessment for Ascertaining the Appropriate Good Manufacturing Practice for Excipients of Medicinal
With timelines closing in for drug product manufacturers to finalize their nitrosamine risk assessments, recalls due to Nitrosamine Drug Substance-Related
Authored by: Srinivas Churya This Quality Insight post presents a concise approach for selection and qualification of Inhouse Reference Standards
Please subscribe for latest posts and news with your email address.
Please subscribe for latest posts and news with your email address.
Be informed about current concerns and focus areas of regulators and auditors; Share your views, comments, hear from industry peers….
List your Job Openings with Qvents; Search for profiles matching the jobs requirements; View profiles, Connect with candidates.
Popular: Warning Letters, Recalls
The U.S. Food and Drug Administration (FDA) has issued a Warning Letter in June 2025 to Chinese drug manufacturer Yiling Pharmaceutical Ltd., (FEI 3011640199) citing serious deficiencies in equipment cleaning and inadequate cross-contamination prevention measures. The facility underwent inspection in...
The USFDA issued a notification on 22 May, 2025 on Data Integrity concerns on reliability and validity of biocompatibility testing and animal safety and performance testing studies conducted for Medical devices by third Party testing facilities. As per the notification...
Dr.Reddys Laboratories
Lupin Limited
Be informed about current concerns and focus areas of regulators and auditors; Share your views, comments, hear from industry peers….
List your Job Openings with Qvents; Search for profiles matching the jobs requirements; View profiles, Connect with candidates.
Popular: Warning Letters, Recalls
The U.S. Food and Drug Administration (FDA) has issued a Warning Letter in June 2025 to Chinese drug manufacturer Yiling Pharmaceutical Ltd., (FEI 3011640199) citing serious deficiencies in equipment cleaning and inadequate cross-contamination prevention measures. The facility underwent inspection in...
The USFDA issued a notification on 22 May, 2025 on Data Integrity concerns on reliability and validity of biocompatibility testing and animal safety and performance testing studies conducted for Medical devices by third Party testing facilities. As per the notification...
Dr.Reddys Laboratories
Lupin Limited
As per EUGMP requirements, EudraLex, Annex 16: Certification by a Qualified Person and Batch Release, the complete manufacturing and distribution
Author: Venkiteswaran.T.K The USFDA’s 2011 guidance on process validation advocates a life cycle approach and defines process validation activities in
In March 2025, Glenmark initiated recall of 23 products (148 lots) in US for cGMP deviations. The recall cover a
According to the EU GMP guidance—“Guidance for Risk Assessment for Ascertaining the Appropriate Good Manufacturing Practice for Excipients of Medicinal
With timelines closing in for drug product manufacturers to finalize their nitrosamine risk assessments, recalls due to Nitrosamine Drug Substance-Related
Authored by: Srinivas Churya This Quality Insight post presents a concise approach for selection and qualification of Inhouse Reference Standards
Popular: Warning Letters, Recalls
The U.S. Food and Drug Administration (FDA) has issued a Warning Letter in June 2025 to Chinese drug manufacturer Yiling Pharmaceutical Ltd., (FEI 3011640199) citing serious deficiencies in equipment cleaning and inadequate cross-contamination prevention measures. The facility underwent inspection in...
The USFDA issued a notification on 22 May, 2025 on Data Integrity concerns on reliability and validity of biocompatibility testing and animal safety and performance testing studies conducted for Medical devices by third Party testing facilities. As per the notification...
Indian regulatory agency, CDSCO has updated the requirements for application and issuance of Export NOC for Unapproved Drugs / Unapproved New Drugs. As per the new procedure published by CDSCO on 7 May 2025, if the drug is approved by...